TRUPANION, INC. TRUP
Our mission is to help loving, responsible pet parents budget and care for their pets.
We provide medical insurance for cats and dogs in the United States, Canada, and certain countries in Continental Europe. Through our data-driven, vertically-integrated approach, we develop and offer high-value medical insurance products, priced to take into account each pet's unique characteristics and coverage level. Our growing and loyal membership base provides us with highly predictable and recurring revenue.
We operate in two reporting segments: subscription business and other business. We generate revenue in our subscription business segment primarily through insurance premiums, which we refer to as subscription payments, from direct-to-consumer products. We operate our subscription business segment similar to other subscription-based businesses, with a focus on achieving a target margin prior to our new pet acquisition expense and acquiring as many pets as possible at our targeted average estimated internal rate of return. Within our subscription business, we also provide "Powered by Trupanion" pet insurance product offerings marketed by third parties, low and medium average revenue per pet products marketed under the brand names Furkin and PHI Direct in Canada, and a Trupanion branded product in Germany and Switzerland. We either directly underwrite or assume full insurance risk for these products through reinsurance arrangements. We provide a full suite of services and support for these products and they are designed to align with the target margin profile of our subscription business segment. Within this segment we also offer products in certain countries in Continental Europe which are currently underwritten by third parties who pay us commissions that we recognize as revenue.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.44B | $1.29B | $1.11B | $905.2M | $699.0M | $502.0M | $383.9M | $304.0M | $242.7M | $188.2M |
| Cost of revenue | $1.21B | $1.11B | $977.6M | $783.0M | $594.6M | $420.1M | $319.0M | $252.6M | — | — |
| Gross profit | $231.0M | $178.8M | $131.0M | $122.2M | $104.3M | $81.9M | $64.9M | $51.4M | $43.0M | $33.3M |
| SG&A | $76.6M | $63.7M | $60.2M | $39.4M | $31.9M | $21.8M | $18.4M | $17.1M | $16.8M | $15.2M |
| Total operating expenses | $216.9M | $188.1M | $171.5M | $164.9M | $139.4M | $86.7M | $66.5M | $52.4M | $45.7M | $40.0M |
| Operating income | $13.8M | -$9.5M | -$40.7M | -$43.0M | -$35.2M | -$4.9M | -$1.9M | -$1.0M | -$2.6M | -$6.7M |
| Interest expense | $13.8M | $14.5M | $12.1M | $4.3M | $10.0K | $1.4M | $1.3M | $1.2M | $533.0K | $218.0K |
| Pre-tax income | $22.0M | -$9.6M | -$45.0M | -$44.2M | -$35.2M | -$5.7M | -$1.6M | -$934.0K | -$1.9M | -$6.9M |
| Income tax | $2.6M | $5.0K | $342.0K | $476.0K | $310.0K | $113.0K | $169.0K | $7.0K | $428.0K | $38.0K |
| Net income | $19.4M | -$9.6M | -$44.7M | -$44.7M | -$35.5M | — | — | — | — | — |
| EPS, basic | 0.45 | -0.23 | -1.08 | -1.10 | -0.89 | -0.16 | — | — | — | — |
| EPS, diluted | 0.45 | -0.23 | -1.08 | -1.10 | -0.89 | -0.16 | -0.05 | -0.03 | -0.05 | -0.24 |
| Shares, diluted (wtd. avg.) | $43.6M | $42.2M | $41.4M | $40.8M | $40.1M | $35.9M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $138.0M | $160.3M | $170.5M | $84.6M | $100.9M | $146.2M | $30.6M | $28.0M | $26.3M | $24.2M |
| Short-term investments | $232.7M | $147.1M | $129.7M | $156.8M | $126.0M | $89.9M | $69.7M | $54.6M | $37.6M | $29.6M |
| Total current assets | $691.1M | $597.3M | $562.1M | $469.1M | $391.0M | $337.0M | $158.8M | $118.0M | $86.6M | $65.4M |
| Property, plant and equipment | $104.8M | $102.2M | $103.7M | $90.7M | $78.0M | $72.6M | $70.4M | $69.8M | $7.9M | $8.5M |
| Goodwill | $39.4M | $37.0M | $43.7M | $42.0M | $32.7M | $31.4M | $0 | — | — | — |
| Other intangibles | $24.1M | $13.2M | $18.7M | $24.0M | $22.7M | $27.1M | $7.7M | $8.1M | $5.0M | $4.9M |
| Total assets | $915.0M | $806.9M | $782.9M | $671.6M | $562.6M | $498.2M | $257.2M | $207.5M | $105.9M | $82.3M |
| Accounts payable | $16.4M | $11.5M | $10.5M | $9.5M | $9.0M | $6.1M | $4.1M | $2.8M | $2.7M | $2.0M |
| Short-term debt | $10.0M | $1.4M | $1.4M | $1.1M | $0 | — | — | — | — | — |
| Total current liabilities | $409.8M | $349.6M | $344.5M | $289.6M | $223.7M | $150.4M | $91.6M | $63.2M | $45.9M | $30.4M |
| Long-term debt | $101.8M | $127.5M | $127.6M | $68.4M | $0 | $0 | $26.1M | $12.9M | $9.3M | $4.8M |
| Total liabilities | $531.1M | $483.6M | $479.2M | $366.3M | $230.4M | $158.3M | $120.4M | $78.3M | $57.4M | $37.6M |
| Retained earnings | -$206.5M | -$225.9M | -$216.3M | -$171.6M | -$126.9M | -$91.4M | -$85.5M | -$83.7M | -$82.8M | -$81.3M |
| Total equity | $383.9M | $323.3M | $303.7M | $305.3M | $332.2M | $339.9M | $136.8M | $129.2M | $48.4M | $44.7M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $89.5M | $48.3M | $18.6M | -$8.0M | $7.5M | $21.5M | $16.2M | $12.7M | $9.7M | $5.0M |
| Depreciation and amortisation | $15.8M | $16.5M | $12.5M | $10.9M | $12.0M | $7.1M | $5.6M | $4.5M | $4.2M | $3.8M |
| Stock-based compensation | $38.3M | $33.4M | $33.2M | $33.4M | $28.2M | $8.9M | $6.8M | $4.8M | $3.4M | $2.9M |
| Capital expenditure | $14.1M | $9.7M | $18.3M | $17.1M | $12.4M | $7.5M | $5.4M | $56.9M | $3.1M | $1.9M |
| Investing cash flow | -$95.9M | -$13.5M | $7.6M | -$67.5M | -$51.9M | -$76.7M | -$28.0M | -$81.5M | -$13.1M | -$6.5M |
| Financing cash flow | -$22.9M | -$4.0M | $59.1M | $60.7M | -$1.1M | $170.8M | $14.0M | $71.2M | $5.1M | $7.7M |
| Buybacks | — | $0 | $0 | $5.8M | $0 | $78.0K | — | — | — | $600.0K |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001371285-26-000081.
Others in SIC 6324
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| UNH | UNITEDHEALTH GROUP INC | $356.47B | 30.0x | 11.8% |
| ELV | Elevance Health, Inc. | $88.37B | 16.2x | 12.5% |
| CI | Cigna Group | $74.65B | 12.7x | 11.2% |
| HUM | HUMANA INC | $48.21B | 40.8x | 31.6% |
| CNC | CENTENE CORP | $33.12B | — | 20.0% |
| MOH | MOLINA HEALTHCARE, INC. | $10.48B | 22.5x | 11.7% |
| OSCR | Oscar Health, Inc. | $9.75B | — | 39.0% |
| ALHC | Alignment Healthcare, Inc. | $2.81B | — | 46.1% |